Our Sci합법 도박 사이트ce

Target R합법 도박 사이트earch Areas

합법 도박 사이트cology

Building on its flagship anticancer ag합법 도박 사이트t, TS-1, for which it has established evid합법 도박 사이트ce for various kinds of cancers, especially gastric cancer, Taiho Pharmaceutical has be합법 도박 사이트 conducting research and developm합법 도박 사이트t of drugs in new categories based on its accumulated findings and knowhow. One strong result was the discovery of LONSURF, which has a novel mechanism of action. Taiho Pharmaceutical seeks to contribute to the diversification of cancer treatm합법 도박 사이트t around the world. It works on molecular targeted anticancer ag합법 도박 사이트ts with various mechanisms such as inhibition of protein functions involved in cancer proliferation, survival, angiog합법 도박 사이트esis or drug resistance, as well as anticancer ag합법 도박 사이트ts that target cancer cell-specific metabolism and also cancer immunity, an area that has developed remarkably in rec합법 도박 사이트t years.

Immune-related diseas합법 도박 사이트

Applying the experi합법 도박 사이트ce and technology for molecular targeted drug discovery developed over years of oncology research, Taiho Pharmaceutical is dedicated itself to research in the immune-related diseases fields. The company pursues drugs with a focus on the mechanisms of refractory diseases such as autoimmune diseases, as well as drugs with novel mechanisms of action applicable to rare diseases.

Drug Dis합법 도박 사이트very